This article is more than 5 years old. Information may no longer be current.

Solx 790 laser receives FDA clearance

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BERLIN — The Solx 790, a 790-nm titanium sapphire laser, received U.S. Food and Drug Administration 510k clearance, company representatives said here at the European Society of Cataract and Refractive Surgeons meeting.

"We are very pleased after this long process to receive our first FDA clearance," Solx CEO and founder Doug Adams told Ocular Surgery News.

According to company literature, the Solx 790 laser penetrates more deeply into the trabecular meshwork than selective trabeculoplasty and causes less tissue damage than other trabeculoplasty procedures.

Studies have shown that the titanium laser trabeculoplasty reduces IOP as well as argon laser trabeculoplasty without causing as much tissue damage and is therefore repeatable. Studies have shown a 25% reduction in "best medicated IOP at 1 year," according to company literature.